Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma
Open Access
- 11 June 2024
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 99 (10) , 1887-1896
Abstract
There is growing interest in multiple myeloma (MM) circulating tumor cells (CTCs), but their rareness in peripheral blood (PB) and inconsistency in cutoffs question their clinical utility. Herein, we applied next‐generation flow cytometry in 550 bone marrow (BM) and matched PB samples to define an optimal CTC cutoff for both transplant‐eligible and transplant‐ineligible newly diagnosed MM (NDMM) patients. Deep phenotyping was performed to investigate unique microenvironmental features associated with CTC dissemination. CTCs were detected in 90% of patients (median 0.01%; range: 0.0002%–12.6%) and increased levels associated with adverse features. Correlations were observed between high CTC percentages and a diffused MRI pattern, a distinct BM composition characterized by altered B‐cell differentiation together with an expansion of effector cells and tumor‐associated macrophages, as well as a greater phenotypic dissimilarity between BM and PB clonal cells. Progression‐free survival (PFS) and overall survival (OS) gradually worsened with each logarithmic increment of CTCs. Conversely, NDMM patients without CTCs showed unprecedented outcomes, with 5‐year PFS and OS rates of 83% and 97%, respectively. A cutoff of 0.02% CTCs was independent of the ISS, LDH, and cytogenetics in a multivariate analysis of risk factors for PFS. The 0.02% CTC cutoff synergized with the MGUS‐like phenotype and the R‐ISS for improving the risk stratification systems. MRD negativity was less frequent if CTCs were ≥0.02% at diagnosis, but whenever achieved, the poor prognosis of these patients was abrogated. This study shows the clinical utility of CTC assessment in MM and provides evidence toward a consensus cutoff for risk stratification.Keywords
All Related Versions
Funding Information
- HORIZON EUROPE European Innovation Council (101097094)
This publication has 34 references indexed in Scilit:
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and managementAmerican Journal of Hematology, 2022
- Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responsesCell, 2021
- Enhancing the R‐ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cellsAmerican Journal of Hematology, 2019
- Multi‐site reproducibility of a human immunophenotyping assay in whole blood and peripheral blood mononuclear cells preparations using CyTOF technology coupled with Maxpar Pathsetter, an automated data analysis systemCytometry Part B: Clinical Cytometry, 2019
- Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysisClinical Lymphoma Myeloma and Leukemia, 2019
- Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspiratesNature Communications, 2017
- The Mutational Landscape of Circulating Tumor Cells in Multiple MyelomaCell Reports, 2017
- Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myelomaLeukemia, 2017
- Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working GroupLeukemia, 2012
- Plasma cell leukemia. Report on 17 casesArchives of internal medicine (1960), 1974